Page 923 - Read Online

Page 20 of 22 Mantovani et al. Hepatoma Res 2020;6:78 I http://dx.doi.org/10.20517/2394-5079.2020.75

97. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver
disease and reduced incidence of type 2 diabetes. Diabetes Care 2015;38:1673-9.
98. Ming J, Xu S, Gao B, et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-
year cohort study. Liver Int 2015;35:2401-7.
99. Li WD, Fu KF, Li GM, et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes
mellitus. World J Gastroenterol 2015;21:9607-13.
100. Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: The Multi-ethnic study of atherosclerosis.
Atherosclerosis 2015;242:211-7.
101. Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-
overweight individuals. Liver Int 2016;36:275-83.
102. Chen GY, Cao HX, Li F, et al. New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes
in East China: Shanghai Baosteel Cohort. J Diabetes Investig 2016;7:206-11.
103. Li Y, Wang J, Tang Y, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population:
Evidence from the Dongfeng-Tongji cohort study. PLoS One 2017;12:e0174291.
104. Ma J, Hwang SJ, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol
2017;66:390-7.
105. Chen SC, Tsai SP, Jhao JY, Jiang WK, Tsao CK, Chang LY. Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type
2 diabetes: a prospective study of 132,377 adults. Sci Rep 2017;7:4649.
106. Liu M, Wang J, Zeng J, Cao X, He Y. Association of NAFLD with diabetes and the impact of BMI changes: a 5-year cohort study based
on 18,507 elderly. J Clin Endocrinol Metab 2017;102:1309-16.
107. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.
Diabetes Care 2018;41:372-82.
108. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes
mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2020:gutjnl-2020-322572.
109. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013;98:3637-43.
110. Cho HJ, Hwang S, Park JI, et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus. Gut Liver
2019;13:440-9.
111. Heo NY. Nonalcoholic fatty liver disease is a stepping stone in the path toward diabetes mellitus. Gut Liver 2019;13:383-4.
112. Mauvais-jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565-82.
113. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of
research gaps. Hepatology 2019;70:1457-69.
114. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73.
115. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes
Study. Diabetes Care 1999;22:756-61.
116. Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol
2014;109:1020-5.
117. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a
community-based cohort study. Am J Gastroenterol 2010;105:1567-73.
118. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and
management. Liver Int 2016;36:936-48.
119. Bertot LC, Jeffrey GP, de Boer B, et al. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-
alcoholic fatty liver disease. Liver Int 2018;38:1793-802.
120. de Lédinghen V, Vergniol J, Gonzalez C, et al. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
Dig Liver Dis 2012;44:413-8.
121. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr
Med Res Opin 2010;26:2183-91.
122. Ertle J, Dechêne A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent
cirrhosis. Int J Cancer 2011;128:2436-43.
123. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease
among type 2 diabetic patients. Diabetes Care 2007;30:1212-8.
124. Cassidy S, Hallsworth K, Thoma C, et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver
disease and associate with glycemic control. Cardiovasc Diabetol 2015;14:23.
125. Mantovani A, Pernigo M, Bergamini C, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver
disease. Metabolism 2015;64:879-87.
126. Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes.
Nutr Metab Cardiovasc Dis 2014;24:663-9.
127. Mantovani A, Rigolon R, Pichiri I, et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized
patients with type 2 diabetes mellitus. PLoS One 2017;12:e0185459.
128. Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD
to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318.